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Summary.-Several radiotherapeutic schedules compatible with continued struc-
tural-functional integrity of the gastrointestinal (GI) mucosa were compared
utilizing the P815X2 murine mastocytoma grown as a solid subcutaneous tumour.
Both the tumour and underlying normal tissues were irradiated during the treat-
ments. The tumour exhibited a Do that increased from 210 rad to 397 rad as the
tumour aged and in all instances demonstrated minimal shoulders in survival
curves. In spite of a relative radioresistance of cells within the solid tumour, quite
effective control of localized disease could be accomplished with radiotherapy
schemes compatible with GI tolerance limits.
Schedules evaluated utilizing this model included acute exposures to 1122 rad,
daily exposure to 187 rad, 5 days/week exposures to 281 rad, twice weekly exposures
(561 rad on Mondays and 374 rad on Thursdays) and a high dose, two fractions per
day, schedule. Tumours were followed for changes in growth patterns during
these schedules. Efficacy of tumour control was determined and schedules were
compared on this basis. Aggressive radiotherapy approaching the tolerance
limits of any of the fractionation schemes proved most effective.
IN THE present communication we
evaluate the efficacy of several radio-
therapeutic approaches used for the treat-
ment of localized subcutaneous tumours
and report results offractionated exposure
schedules that are limited by normal
tissue (underlying gastrointestinal mucosa)
tolerance. Seven days per week, 5 days
per week, intermittent high dose schedules
and acute exposure experiments were
selected so that intact, functional gastro-
intestinal mucosa would be maintained
throughout the therapeutic efforts. The
P815X2 murine mastocytoma used in
these studies demonstrates many charac-
teristics which are advantageous in a
model system: The tumour may be
grown and evaluated in DBA/2 mice as
a solid subcutaneous primary, in meta-
static foci or as an ascites tumour. It
is responsive to chemotherapeutic (Hage-
mann, Schenken, and Lesher, 1973; Hage-
mann, et al. unpublished), immunological
(Faanes, Choi and Good, 1973) and radio-
therapeutic manipulation. The tumour
grows in a predictable fashion following
subcutaneous implantation, metastasizes
to lung, spleen and lymph nodes in an
ordered pattern, and demonstrates in-
vasiveness and differentiation patterns
similar to many human neoplasms
(Schenken, et al. unpublished).
MNIATERIALS AND METHODS
Tuonur. The P815X2 murine masto-
cytoma used in these studies wras originally
described by Dunn and Potter (1957).
The cells are maintained in our laboratory by
serial inoculation of suspension type cultures
as described by Schindler, Day and Fisher
(1959). Primary tumours were establishedP815X2 RADIOTHERAPEUTIC CONTROL
in DBA/2 mice (Jacksoni Laboratories, Bar
Harbor, Maine) by the subcutaneous (lower
back) inoculation of 1.0 x 106 log phase
cells from such suspension cultures. By
Day 7 post inoculation, tumours have
grown to readily measurable size and meta-
static involvement is detectable, although
not severe.
Irradiation.-Partial abdomen irradiation
was performed at various times following
inoculation of the tumour. A beam incident
to the lower back of the animal was used.
Although beams were adjusted to include
the tumour beds, areas of underlying normal
tissue were also purposely irradiated. Fields
extended from slightly posterior to the renal
beds to a line through the iliofemoral joints.
Physical parameters of irradiation were
275 kVcp, 20 mA, 0-5 mm A1, 1.0 mm Cu
added filtration, h.y.l.- 1.8 mm Cu, ex-
posure rate 117 rad/min.
Treatmnent schedules.-Animals were inocu-
lated with 1.0 x 106 P815X2 tumour cells
on Day 0. On Day 6 post inoculation, groups
of 10 animals each were started on the
following classes of treatment schedules:
A-7 day/week 94, 140 or 187 rad/day;
B 5 day/week (Monday-Friday) 47, 94, 187
or 281 rad/day; C-561 rad Monday followed
by 94 rad/day Tuesday-Friday; D-561 rad
Monday followed by 374 rad Thursday; and
E 234 rad, wait 4 h then an additional 234
rad on Monday followed by 234 rad, wait 4 h
and a second 234 rad on Tuesday. Several
groups of animals were also given varying
acute exposures of radiation (up to 1122
rad) on Day 7 post inoculation only. All
radiation exposures were given at 9 a.m. on
treatment days.
Primary tumour growth. Measurements
of tumour length and width (to the nearest
mm)were made at daily intervals from
Day 7 to Day 21 post inoculation. Tumour
area defined as 7r(length + width/4)2 was
calculated for each animal and mean tumour
area + s.e. was calculated daily for each
experimental group. It has previously been
verified by Schenken et al. (1974), that
tumour area is proportional to tumour
volume, mass and cellularity during growth
of the solid P815X2 mastocytoma.
In addition to group changes in tumour
size, individual animals were followed for
daily tumour area changes; daily mean
changes of tumour size were computed and
overall mean tumour area changes per
day were subsequently calculated for each
group.
Cell survival analysis.-Solid subcuta-
neous P815X2 tumours 7, 14 and 21 days
old were irradiated in situ with graded
exposures of x-rays to determine the in vivo
cell survival curves for the tumours of
different age. Following radiation exposure,
tumours were excised aseptically and single
cell suspensions of tumour cells prepared.
Cells were assayed for clonogenicity (sur-
vival) by using an in vitro clot cloning assay.
Details ofthe procedure have been previously
described by Schindler (1964).
RESULTS
A. Acute exposure
Table I summarizes the results of
plasma clot cloning assays performed
following in vivo irradiations of solid
tumours 7, 14 and 21 days old. The
7-day tumour demonstrates a response
typical of a homogenous population with
an extrapolation number, N, no greater
TABLE I.--P815X2 in vivo Cell Survivalfor P815X2 Turnours 7, 14 and 21
Days Post Inoculation
Exposure
(rad) CE*: 7 day tumour(%) CE: 14 day tumour(%) CE: 21 day tumour (%)
0 95± 10 100±5 100±6
94 75± 15 67±4 79±4
187 50i7 46+9 56±3
468 9i2 16±5 33±4
748 1'5±0.5 8i1-5 15i3 935 2-0±0-7 35+1- 2 5±2 1496 0-25±0 3 1-6±04 2±0-9
(Subpopulations)
N <1-9 A: 1-0 B: ? 1.0
Do 210 rad A: 220 rad B: 397 rad 397 rad
* Cloning efficiency.
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than 1-8 to 2-0 and a Do of 210 rad. The
response ofthe intermediate aged tumours
of 14 days suggests that in addition to a
population of cells with a Do of 210 rad, a
second more radioresistant sub-popula-
tion of cells exists with a Do of approxi-
mately 374 rad. The advanced tumours
of 21 days demonstrate an almost com-
plete shift to a nmore radioresistant
population with an N of IP0 and a Do
of 407 rad.
Such a shift to a more radioresistant
population as the tumour becomes older
may be attributed to several factors, but
is most probably related to an expansion
of a Go type of hypoxic compartment.
Cloning assays of unirradiated 21-day
tumours suggest that 95+% of the cells
present in the tumour are potentially
mitotic and can give rise to clones in
plasma clot gels. However, microscopic
evaluation ofmitotic activity and 3H-TdR
incorporation in such tumours indicates
that the proliferative fraction is exceed-
ingly small. By Day 21 post inoculation,
the 3H-TdR labelling index has dropped
to less than 200%. The increased ap-
pearance of metachromasia, increased
glycoprotein content and heightened hist-
amine granularity in many older tumours
is also consistent with a picture of greater
cellular differentiation.
The growth patterns seen following
single exposures given to 7-day old
P815X2 tumours are shown in Fig. 1
and are summarized in Table 11; 1122 rad
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FIG. 1. The response of P815X2 subcutaneous solid tumours to acute exposures of x-rays givenI
Day 7. (A, control; B, 187 rad; C, 468 iad; D, 701 iad; E, 1122 rad.) Lifespan of animals
Groups A, B, C and D = 26 days post inoculation. Group E = 36 (lays post inioculationi.
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TABLE II. Tumour Growth and Animal
Death following Acute Exposures given
Day 7 Post Inoculation
Exposure
(rad)
0
94
187
468
701
1122
1870
2805
3740
4675
AMean area*
increase/day
(Cm2)
0 28±0 05
0 28±0 06
0 26±0 03
0 26±0 04
0 24±0 05
0 20±0 05
0 12±0 04
0 10±0 03
0 07±0 02
0 04±0 03
Tumour
size at
death
(cm2)
4 45±0 40
4 25±0 75
missing
3 70±0 55
3 60±0 40
2 60±0 30
1 30±0 40
1 90±0-30
1 05±0 10
1 07±0 25
AMean animal
survival
time
days post
inoculation
26-0±2-5
25 0± 1 5
26 0±1 2
26 3±2 0
26 0±2 1
36 i4 ±0
16 8±1 8
12 6±2 0
11 2±0 1
12 8±2 5
* Calculated from individual (laily tumour area
changes, Day 7 to animal death.
was selected as the practical therapeutic
upper limit of exposure in this series of
experiments because it represents a maxi-
mum well tolerated exposure for the
intestine underlying the tumour. Ex-
posures in excess of 1122 rad result in
decreased animal survival due to gastro-
intestinal toxicity. Exposures of 94 or
187 rad resulted in no change in subse-
quent solid tumour growth. Exposures
of 468 rad resulted in slightly reduced
tumour growth (approximately 87%o of
control). Exposures of 1122 rad (curve
E of Fig. 1) not only caused reduction in
growth rate but resulted in substantial
shrinkage of tumour mass. Although
acute exposures ranging up to 701 rad
resulted in increased degrees of tumour
control, they resulted in no significant
increase in animal lifespan. It will be
noted from Table II that lifespan is
increased and mean tumour size at
death is decreased greatly as radiation
exposure is increased to 1122 rad.
As may also be noted from tumour
growth rate data given in Table II,
that in " superlethally " irradiated (in-
testinal exposure greater than 1122 rad)
animals there is a continuing proportional
decrease oftumour growth with increasing
radiation exposure. With higher doses,
tumour area increase per day drops
(doubling times increase) and size at
death decreases. Although the tumour
size at death must certainly be less in
those animals with decreased survival
times, all of the tumour sizes for animals
irradiated 1870-3740 rad are much smaller
than those of age-matched control ani-
mals. Shortened survival times for ex-
posures of 1870 rad and up are the
result of excessive damage to the in-
testinal mucosa irradiated during tumour
treatment.
B. Equi-dose fractionated exposures
The results of experiments where
tumours were irradiated, 94, 140 or
187 rad daily, commencing on Day 7
post inoculation and ending on Day 21
post inoculation are summarized in Fig. 2.
Animals whose entire intestinal mucosa
is irradiated with 281 rad daily will only
accumulate 9 such successive daily ex-
posures(HagemannandConcannon,unpub-
lished); the partial abdominal irradiation
in this study affords sufficient increased
gastrointestinal tolerance to accumulate
14 doses. Because ofsuch limiting gastro-
intestinal toxicity, 281 rad/day 7
days/week exposures were eliminated from
this study. From the data summarized
in Fig. 2 it appears that very encouraging
control of local disease can be obtained
with doses of 187 rad/day given 7 days
per week, such exposures being well
within normal gut tolerance levels.
However, if one compares the growth
of P815X2 tumours during 5 days/week
treatment with growth seen during 7 days/
week radiotherapy schedules, very
pronounced differences may be noted.
As illustrated in Fig. 3, a loss of control
of local disease appears to result from
the weekend gaps in the 5 days/week
radiation schedule; tumour control is
not regained until well into the next
week's exposure schedule. It also ap-
pears that an accelerated growth rate or
compensatory proliferative response re-
sults from the 2 non-treatment days in a
5 days/week radiation schedule. The loss
of control and compensatory growth
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FIG. 2.-Growth curves for 7 days/week radiotherapy schedules (A, control; B, 94 rad/day; C, 140
rad/d; D, 187 rad/d); treatment commences Day 7 post inoculation and is continued through
Day 21 post inoculation. Time axis is for days after start of treatment. Mean survival time
for all groups = Day 19 of treatment schedule (Day 26 post inoculation).
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FIG. 3.-Growth curvesfor 5days/week radiotherapy schedules (A,control; B, 47rad/d; C, 94 rad/day;
D 187 rad/d; E, 281 rad/d). Treatment days are 0-4, 7-11 and 14-18. Mean survival time for
all groups = Day 19 of radiation schedule (Day 26 post inoculation). Time axis is for days
after start of treatment.
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spurt seen as the result of therapeutic
gaps during the 2 non-treatment weekend
days of 5 days/week radiotherapy sche-
dules may be noted in the growth curves
of groups receiving 5 days/week exposures
as low as 47 rad or as high as 281 rad.
If one calculates the overall efficiency
of tumour control per unit of radiation
exposure for both 5 and 7 days/week
modes of therapy, it may be concluded
that by conversion to 7 days/week ex-
posure, the efficiency of P815X2 tumour
control per unit of exposure may be
increased as much as 76% and the loss
oftumour control associated with weekend
gaps in therapy is eliminated.
N
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cr
cr
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C. Selected fractionated exposures
Previous experience in our laboratory
(Hagemann and Concannon, 1974) sug-
gested that the classes of exposures out-
lined in Fig. 4 would all be well tolerated
by the gastrointestinal mucosa concomi-
tantly irradiated during tumour treat-
ment. The irradiation patterns used in
Groups B-E of Fig. 4 all result in tumour
exposures of 935 rad/week, yet great
differences in tumour control are apparent.
The most effective schedule (Group E)
resulted in mean tumour sizes limited to
25% of untreated controls. The mean
animal survival time for Group E was
increased from 26 days to 34-5 days.
o 2 4 6 8 lo 12 14 16 18 20 22 24
DAYS POST IRRADIATION
FiG. 4. P815X2 growth curves following " high dose " schedules. Mondays are Days 0, 7, 14.
(A, control; B, 187 rad/day, Monday-Friday; C, 234rad x 2 Monday + 234 rad x 2 Tuesday; D,
561 rad Monday + 94 rad/day Tuesday-Friday; E, 561 rad Monday + 374 rad Thursday.) Mean
survival time for Group A, B, C and D = Day 19 of radiation schedule (Day 26 post inoculation).
Mean survival for animals in Group E is extended to Day 34 -5 post inoculation. Time axis is for
days after start of treatment.
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TABLE III. CoMpartson of 935 rad per Week Radiotherapy Schedules
Type of exposure
7 day per week
5 day per week
234 rad R x 2 AIM+
234 rad x 2 T
561 rad M+94 rad T-Th
561 rad M+374 rad Th
Exposure per week
(rad)
982
935
935
935
935
Average exposure
per day
(rad)t
140
187
468
187
468
Tumour size Treatment (00 control) efficiency*
55 14-3
72 9,3
62 12-3
48 17-:3
25 25 0
* Treatment efficiency is calculated by the following formula:
T.E. 1 (treated tumour size (cm2)/control tumouir size (cm2) x 105 rad)
T.E. Total radiation exposure (rad)
Larger values of T.E. indicate more efficient tumour treatment than those with smaller values. Total
exposure for these groups (3 weeks of treatment) was 2805 rad.
t Per treatment day.
Mean survival times for animals in other
treatment groups were indistinguishable
from controls.
A further comparison of 935 rad/week
radiotherapy schedules is presented in
Table III. Exposures equally divided
over 7 days/week fractionation patterns
resulted in tumours limited to 50%0 of
control. The same total exposure given
5 days/week resulted in a lessened tumour
response of 72% of control. If the
weekly total of 935 rad was divided into
4 equal exposures of 234 rad given over
2 days (curve C of Fig. 4), tumour growth
was controlled somewhat better than
with 5 days/week exposures, but not as
well as with 7 days/week exposures.
A further improvement of tumour control
was seen following the 561 rad Monday +
94 rad/day Tuesday-Friday treatment
(curve D of Fig. 4). The greatest control
of local disease resulted from the 561 rad
Monday + 374 rad Thursday schedule.
In order to compare efficiencies of
tumour control per unit of radiation
exposure, the calculations summarized in
the column entitled " treatment effi-
ciency" were made. Treatments result-
ing in no control of the primary result
in TE values of 0 00; treatments that
result in effective control of local disease
result in TEs that are correspondingly
higher. Ifa treatment resulted in tumour
growth greater than would result from
sham treatment the TE would be a
negative number. Thus expressed, the
most inefficient method of tumour control
would be the 5 days/week schedule and
the most efficient method used would
be the 561 rad Monday and 374 rad
Thursday schedule.
DISCUSSION
Our initial approach to evaluating
the radiotherapeutic responsiveness of
solid subcutaneous P815X2 tumours in-
volved definition of a model whereby
critical normal tissue would, of necessity,
be irradiated concomitantly with local
tumour. We chose the lower back for the
site of subcutaneous inoculation, thereby
requiring that any radiation beam incident
to the tumour would irradiate a sub-
stantial portion of the underlying colon
and small intestine. Data presented by
Lesher and Lesher (1974), Hagemann et al.
(unpublished), and Hagemann, Sigdestad
and Lesher (1972) suggested the following
general guidelines for gastrointestinal tol-
erance following total abdominal radia-
tion exposures: (1) Generally, exposures
in excess of 1216 rad/week are not well
tolerated by the intestinal mucosa; (2)
similarly, multifraction daily exposures
to the gut should be less than 281 rad/frac-
tion; (3) a schedule of 935 rad in 2 days
will be well tolerated if divided doses
of 234 rad/fraction are used; (4) 561 rad
represents an exposure which will alter
mucosal cellularity but will not alter
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crypt multiplicity. Repeated exposures
of 561 rad could, with adequate time
for interfraction repopulation, be well
tolerated.
Several general aspects for the P81.5X2
tumour also relate to considerations of the
model: (1) Cloning data suggest that by
Day 7 post-inoculation, metastatic growth
is minimal, yet detectable; (2) almost all
cells in the primary tumour are clono-
genic; are capable of sustained pro-
liferation; and from data presented in
this paper: (3) the cells within a solid
P815X2 tumour do not have much
capacity for the accumulation and/or the
repair of radiation damage (low extra-
polation number and narrow shoulder
for both young and old tumours); (4) the
Do range of 210-407 rad indicates a
cell type which is not excessively sensitive
to radiation exposure.
A limited approach to the radio-
therapeutic control of local disease (the
solid P815X2 subcutaneous primary)
evolved from such considerations of nor-
mal tissue tolerance and tumour respon-
siveness. The model further imposed
that when the animal presented for
therapy local disease was quantifiable
and that metastatic involvement had
already occurred. We know from the
onset of our experiments that although
local disease might be successfully elimin-
ated, animals would eventually die from
metastatic burden. We have successfully
designed a surgical technique whereby
the subcutaneous tumour could be re-
moved at Day 7 and animals would then
live to 34 days post inoculation instead of
the normal 26 days (unpublished ob-
servation). Therefore it was thought that
a truly successful radiotherapeutic ap-
proach to the control of local disease
should result in an increased lifespan
approaching this order of magnitude, and
that control of the primary should be
established as early as possible after
Day 6. In all probability these results
of aggressive radiotherapeutic efforts
would approach the configuration one
would expect using " optimal " efforts at
ablating localized P815X2 disease. Radio-
therapy alone, because treatment is initi-
ated after the onset of metastatic in-
volvement, could not be expected to
result in animal cures. At best, altera-
tions in animal survival times would be
similar to those seen following surgical
removal of the primary tumour on
Day 7.
Of those schedules tested which were
compatible with continued maintenance
of a functional gastrointestinal mucosa,
(A: acute exposures of 187, 468, 701 and
1122 rad; B: 7 days/week exposures of
94, 140 and 187 rad/day; C: 5 days/week
exposures of 47, 94, 187 or 281 rad/day,
and D: selected high dose patterns
limited to 935 rad/week), the two most
effective schedules in terms of tumour
control did indeed result in an increased
lifespan to approximately 34 days. The
acute exposure of 1122 rad resulted in
dramatic tumour regression and mean life-
spans of 36-0 days. The high dose
schedule of 561 rad on Monday of each
week followed by 374 rad on Thursdays
resulted in prompt control of tumour
growth and mean animal lifespans ex-
tended to 34-5 days. All ofthe remaining
exposure schedules used in this series,
although eliciting varying degrees of
control on the localized tumour, resulted
in no significant increase in mean survival
times.
The increased control of tumour
growth as exposure per fraction increased
seen for the 7 days/week schedules (Fig.
2) and the 5 days/week schedules (Fig. 3)
is not surprising for the cell survival data
presented in Table I suggest that there
is very little shoulder to the survival
curves; small increases in exposure per
fraction will generate differences in cell
kill that will eventually be manifest as
changes in tumour size. Yet cell killing
per se cannot account for all the differen-
tial effects seen in these series. It must
be considered that the subcutaneous
P815X2 tumour does not contain a
static population of cells at risk to
fractionated radiotherapy. Such experi-
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mental tumours generally have shown
several characteristics that determine
overall radioresponsiveness to fractionated
radiation exposure. These characteristics
include interfraction repair of sublethal
damage, redistribution of cells within the
proliferative compartment, reoxygenation
of tumour tissue and repopulation of
proliferative compartments by recruit-
ment of quiescent cells and/or shortening
of mean cell cycle times.
The data presented in Fig. 3 for 5
days/week radiation schedules demon-
strate that as a result of weekend gaps in
treatment increased tumour growth is
seen from Monday to Wednesday of the
following weeks, and that by Wednesday
of each week (Days 2, 9 and 16 of Fig. 3)
this increased growth is again controlled.
This compensatory growth spurt seen
following weekend gaps in therapy most
probably accounts for the differences
seen between the 5 days/week and 7
days/week treatments summarized in
Table III. Our preliminary measures
of 3H-TdR labelling index and DNA
synthesis rates in radiation perturbed
tumours indicates that proliferative acti-
vity may be increased as much as 180%
for as long as 72 h following the radiation
exposure. Such increased proliferation
would account for the increased tumour
mass resulting from weekend therapeutic
gaps and an increase in proliferative cells
at risk, and/or an increase in the oxygen-
ated compartment of the tumour would
account for a short-term increase in cell
kill following weekend gaps in therapy.
We are presently attempting to determine
the magnitude of these fluxes in cell
populations within the P815X2 solid
tumours in an attempt to predict more
accurately how such compensatory re-
sponses in a solid tumour could be
utilized for design of more efficacious
approaches to the control of local disease.
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